先端巨大症の世界市場レポート 2025年

先端巨大症市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR17.6%で49億2,000万米ドルに成長します。予測期間の成長は、先端巨大症治療の研究開発活動への投資、スクリーニングプログラムの増加、ヘルスケア支出の増加、低侵襲治療オプションへの需要の増加などに起因しています。予測期間の主な動向には、先端巨大症の革新的治療、先端巨大症の標的治療開発、強力な医薬品パイプライン、治療オプションの進歩、高度個別化医療などが含まれます。

糖尿病などのホルモン性疾患の罹患率の上昇が先端巨大症市場の成長を促進すると予想されます。ホルモン性疾患（内分泌疾患）は内分泌系の機能不全から発生し、中でも糖尿病は最も一般的で影響も大きいです。先端巨大症やその他の内分泌疾患は、成長ホルモンやコルチゾールなどの特定のホルモンが過剰に分泌されることで発症します。さらに、成長ホルモンレベルの上昇はインスリン産生に影響を及ぼし、先端巨大症を持つ人の約50％にインスリン抵抗性または2型糖尿病を引き起こす可能性があります。例えば、2024年3月、英国のOffice for Health Improvement and Disparitiesのデータによると、2022年3月と2023年3月の間に、推奨される8つのケアプロセスをすべて完了した1型糖尿病患者の割合は22％増加し、2型糖尿病では21％増加しました。HbA1cの目標値達成率は37.9%に達し、全国糖尿病監査（NDA）の報告で過去最高となりました。その結果、ホルモン性疾患の有病率の増加が先端巨大症市場を前進させる重要な要因となっています。

遺伝子異常の有病率の高まりは、先端巨大症市場の将来的な拡大の主要な促進要因になると考えられています。遺伝子異常は、しばしば遺伝子欠陥や遺伝子障害として知られ、個人の遺伝子のDNA配列に現れる変化や突然変異を包含し、非典型的な特徴、機能、特性をもたらす可能性があります。下垂体による成長ホルモン（GH）の過剰産生を特徴とする疾患である先端巨大症は、非がん性腺腫と関連することが多く、これは散発的に発生することもあれば、特定の遺伝子異常と関連することもあります。例えば、2022年2月現在、スイスに本部を置く政府間機関である世界保健機関（WHO）のデータによると、先天性異常は毎年生後28日以内に24万人の新生児の死亡に寄与しています。さらに、1カ月から5歳までの17万人の子供が、心臓病、神経管欠損症、ダウン症などの先天異常によって命を落としています。その結果、遺伝子異常の発生率が上昇しており、先端巨大症市場を前進させる準備が整っています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界先端巨大症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の先端巨大症市場：成長率分析
• 世界の先端巨大症市場の実績：規模と成長, 2019-2024
• 世界の先端巨大症市場の予測：規模と成長, 2024-2029, 2034F
• 世界先端巨大症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の先端巨大症市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 異所性先端巨大症
• 先端巨大症成長ホルモン別
• 世界の先端巨大症市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• GHとIGF-Iの測定
• 成長ホルモン抑制試験
• イメージング
• その他の診断
• 世界の先端巨大症市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の先端巨大症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• ソマトスタチン類似体
• ドーパミン作動薬
• 成長ホルモン拮抗薬
• 手術
• 放射線
• その他の治療法
• 世界の先端巨大症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の先端巨大症市場異所性先端巨大症の種類別の分類、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍誘発異所性先端巨大症
• 非腫瘍性異所性先端巨大症
• 世界の先端巨大症市場、成長ホルモンによる先端巨大症のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 一次成長ホルモン過剰
• 二次成長ホルモン過剰

第7章 地域別・国別分析

• 世界の先端巨大症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の先端巨大症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 先端巨大症市場：競合情勢
• 先端巨大症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• AstraZeneca plc
• GlaxoSmithKline plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH.
• Amgen Inc.
• Allergan Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Ipsen Pharma S.A.
• Hikma Pharmaceuticals PLC
• Lupin Ltd.
• Recordati S.p.A.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 先端巨大症市場2029：新たな機会を提供する国
• 先端巨大症市場2029：新たな機会を提供するセグメント
• 先端巨大症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acromegaly is an infrequent hormonal disorder stemming from the excessive production of growth hormone by the pituitary gland, a small structure situated at the base of the brain. This surplus of growth hormone triggers the enlargement and thickening of bones and tissues, predominantly affecting areas such as the hands, feet, and face.

The primary classifications of acromegaly encompass ectopic acromegaly and acromegaly due to growth hormone. Ectopic acromegaly is a rare medical condition characterized by the overproduction of growth hormone (GH) originating from a source outside the pituitary gland. The diagnostic methods employed include GH and IGF-I measurement, growth hormone suppression tests, imaging, and various others, which can be administered through diverse routes, including oral, parenteral, and others. Treatment options are available, ranging from medications, somatostatin analogues, dopamine agonists, and growth hormone antagonists to surgical procedures, radiation therapy, and other approaches. These treatments find application across various end users, including hospitals, specialty clinics, homecare settings, and others.

The acromegaly market research report is one of a series of new reports from The Business Research Company that provides acromegaly market statistics, including acromegaly industry global market size, regional shares, competitors with an acromegaly market share, detailed acromegaly market segments, market trends and opportunities and any further data you may need to thrive in the acromegaly industry. This acromegaly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acromegaly market size has grown rapidly in recent years. It will grow from $2.15 billion in 2024 to $2.57 billion in 2025 at a compound annual growth rate (CAGR) of 19.6%. The growth in the historic period can be attributed to increasing prevalence of acromegaly therapeutics, growing awareness about acromegaly, government initiatives, demand for effective treatments.

The acromegaly market size is expected to see rapid growth in the next few years. It will grow to $4.92 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to investments in research and development activities for acromegaly treatments, growing number of screening programs, rising healthcare spending, increasing demand for minimally invasive treatment options. Major trends in the forecast period include innovative treatments for acromegaly, development of targeted therapies for acromegaly, strong pipeline of drugs, advancements in treatment options, advanced personalized medicine.

The rising incidence of hormonal diseases, such as diabetes, is expected to drive growth in the acromegaly market. Hormonal diseases, or endocrine disorders, arise from dysfunctions within the endocrine system, with diabetes being among the most common and impactful. Acromegaly and other endocrine disorders can occur due to the excessive production of certain hormones, like growth hormone or cortisol. Additionally, elevated growth hormone levels can affect insulin production, leading to insulin resistance or type 2 diabetes mellitus in approximately 50% of individuals with acromegaly. For example, in March 2024, data from the UK's Office for Health Improvement and Disparities revealed that between March 2022 and March 2023, the percentage of type 1 diabetes patients completing all eight recommended care processes increased by 22%, and for type 2 diabetes, by 21%. The proportion achieving target HbA1c levels reached 37.9%, the highest ever reported by the National Diabetes Audit (NDA). Consequently, the growing prevalence of hormonal diseases is a key factor propelling the acromegaly market forward.

The escalating prevalence of genetic abnormalities is poised to be a key driver for the future expansion of the acromegaly market. Genetic abnormalities, often known as genetic defects or genetic disorders, encompass alterations or mutations that manifest in the DNA sequence of an individual's genes and can lead to atypical features, functions, or characteristics. Acromegaly, a condition characterized by the overproduction of growth hormone (GH) by the pituitary gland, is frequently associated with noncancerous adenomas, which can occur sporadically or be linked to specific genetic abnormalities. For instance, as of February 2022, data from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, indicated that congenital abnormalities contribute to the mortality of 240,000 newborns within the first 28 days of life annually. Additionally, an extra 170,000 children aged between 1 month and 5 years lose their lives due to congenital abnormalities, encompassing conditions like heart defects, neural tube defects, and Down syndrome. Consequently, the rising incidence of genetic abnormalities is poised to propel the acromegaly market forward.

Leading companies in the acromegaly market are prioritizing the development of innovative products and solutions, such as generic lanreotide, to expand treatment options and improve patient outcomes. Generic lanreotide is an unbranded version of the medication used to treat acromegaly and certain neuroendocrine tumors. As a somatostatin analogue, it helps reduce growth hormone secretion, making effective treatment more accessible for patients. For example, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based company specializing in generic drugs, launched the first generic version of Sandostatin LAR Depot in the U.S. This injectable suspension, octreotide acetate, is indicated for treating acromegaly and severe diarrhea linked to carcinoid syndrome, providing essential therapy access to patients in need.

In July 2024, AstraZeneca plc, a UK-based multinational pharmaceutical and biotechnology company, acquired Amolyt Pharma for $1.05 billion. This acquisition enhances AstraZeneca's pipeline in rare disease treatments, particularly in endocrine and metabolic disorders, as Amolyt's innovative therapies complement the company's commitment to advancing patient care and addressing unmet medical needs. Amolyt Pharma, a France-based clinical-stage biopharmaceutical company, specializes in developing treatments for rare endocrine diseases, including eneboparatide for hypoparathyroidism and AZP-3813, a peptide antagonist for acromegaly.

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acromegaly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The acromegaly market consists of revenues earned by entities by providing hormone replacement therapy, pituitary radiotherapy and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The acromegaly market also includes sales of octreotide, lanreotide and somavert. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acromegaly Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acromegaly market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acromegaly ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acromegaly market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Ectopic Acromegaly; Acromegaly Due To Growth Hormone
• 2) By Diagnosis: GH And IGF-I Measurement; Growth Hormone Suppression Test; Imaging; Other Diagnosis
• 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 4) By Treatment: Medication; Somatostatin analogues; Dopamine Agonists; Growth Hormone Antagonist; Surgery; Radiation; Other Treatments
• 5) By End Users: Hospitals; Specialty Clinics; Homecare; Other End Users
• Subsegments:
• 1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly; Non-Tumor-Induced Ectopic Acromegaly
• 2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess; Secondary Growth Hormone Excess
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; Merck & Co Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acromegaly Market Characteristics

3. Acromegaly Market Trends And Strategies

4. Acromegaly Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Acromegaly Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acromegaly PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acromegaly Market Growth Rate Analysis
• 5.4. Global Acromegaly Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acromegaly Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acromegaly Total Addressable Market (TAM)

6. Acromegaly Market Segmentation

• 6.1. Global Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ectopic Acromegaly
• Acromegaly Due To Growth Hormone
• 6.2. Global Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• GH And IGF-I Measurement
• Growth Hormone Suppression Test
• Imaging
• Other Diagnosis
• 6.3. Global Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.4. Global Acromegaly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Somatostatin analogues
• Dopamine Agonists
• Growth Hormone Antagonist
• Surgery
• Radiation
• Other Treatments
• 6.5. Global Acromegaly Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End Users
• 6.6. Global Acromegaly Market, Sub-Segmentation Of Ectopic Acromegaly, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor-Induced Ectopic Acromegaly
• Non-Tumor-Induced Ectopic Acromegaly
• 6.7. Global Acromegaly Market, Sub-Segmentation Of Acromegaly Due To Growth Hormone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Growth Hormone Excess
• Secondary Growth Hormone Excess

7. Acromegaly Market Regional And Country Analysis

• 7.1. Global Acromegaly Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acromegaly Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acromegaly Market

• 8.1. Asia-Pacific Acromegaly Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acromegaly Market

• 9.1. China Acromegaly Market Overview
• 9.2. China Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acromegaly Market

• 10.1. India Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acromegaly Market

• 11.1. Japan Acromegaly Market Overview
• 11.2. Japan Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acromegaly Market

• 12.1. Australia Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acromegaly Market

• 13.1. Indonesia Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acromegaly Market

• 14.1. South Korea Acromegaly Market Overview
• 14.2. South Korea Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acromegaly Market

• 15.1. Western Europe Acromegaly Market Overview
• 15.2. Western Europe Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acromegaly Market

• 16.1. UK Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acromegaly Market

• 17.1. Germany Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acromegaly Market

• 18.1. France Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acromegaly Market

• 19.1. Italy Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acromegaly Market

• 20.1. Spain Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acromegaly Market

• 21.1. Eastern Europe Acromegaly Market Overview
• 21.2. Eastern Europe Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acromegaly Market

• 22.1. Russia Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acromegaly Market

• 23.1. North America Acromegaly Market Overview
• 23.2. North America Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acromegaly Market

• 24.1. USA Acromegaly Market Overview
• 24.2. USA Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acromegaly Market

• 25.1. Canada Acromegaly Market Overview
• 25.2. Canada Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acromegaly Market

• 26.1. South America Acromegaly Market Overview
• 26.2. South America Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acromegaly Market

• 27.1. Brazil Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acromegaly Market

• 28.1. Middle East Acromegaly Market Overview
• 28.2. Middle East Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acromegaly Market

• 29.1. Africa Acromegaly Market Overview
• 29.2. Africa Acromegaly Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acromegaly Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acromegaly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acromegaly Market Competitive Landscape And Company Profiles

• 30.1. Acromegaly Market Competitive Landscape
• 30.2. Acromegaly Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Acromegaly Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. AstraZeneca plc
• 31.4. GlaxoSmithKline plc
• 31.5. Eli Lilly and Company
• 31.6. Gilead Sciences Inc.
• 31.7. Boehringer Ingelheim International GmbH.
• 31.8. Amgen Inc.
• 31.9. Allergan Inc.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Mylan N.V.
• 31.12. Ipsen Pharma S.A.
• 31.13. Hikma Pharmaceuticals PLC
• 31.14. Lupin Ltd.
• 31.15. Recordati S.p.A.

32. Global Acromegaly Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acromegaly Market

34. Recent Developments In The Acromegaly Market

35. Acromegaly Market High Potential Countries, Segments and Strategies

• 35.1 Acromegaly Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acromegaly Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acromegaly Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer